Gilead corrects Q2 2026 Europe Odefsey sales to $58 million

Reuters2026/08/05 01:47

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Gilead issued a corrected version of its second-quarter 2026 earnings release to fix an error in the product sales table.
Odefsey sales in Europe for the three months ended June 30, 2026 were revised to USD 58 million from USD 28 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Gilead corrects Q2 2026 Europe Odefsey sales to $58 million

You may also like

Crypto prices